Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
J Endocr Surg. 2017 Dec;17(4):153-159. English. Original Article. https://doi.org/10.16956/jes.2017.17.4.153
Chang MC .
Department of Surgery, Dankook University College of Medicine, Cheonan, Korea. changmc@dankook.ac.kr
Abstract

Purpose

There are conflicting results about bone mineral density (BMD) after thyroid-stimulating hormone (TSH) suppression in thyroid cancer treatment. This study used the Korea National Health and Nutrition Examination Survey (KNHANES) data to investigate BMD of thyroid cancer patients in Korea.

Methods

The data were collected from 2008 to 2011 of the KNHANES IV–V. Among a total of 37,753 participants, 18,618 subjects were included. Osteopenia and osteoporosis were evaluated according the past history of thyroid cancer. Subgroups of women and post-menopausal women were analyzed using the same method.

Results

Among the 18,618 subjects, 80 thyroid cancer cases were observed. There was no significant difference in osteopenia and osteoporosis with or without thyroid cancer history (P=0.783). In the subgroup analyses of women, no difference was observed in BMD according thyroid cancer history (P=0.685). In the post-menopausal women, osteopenia and osteoporosis were less frequent in thyroid cancer cases in univariate analysis (P=0.003), but that was not significant in multivariate analysis (P=0.095).

Conclusion

Although the KNHANES had a small number of thyroid cancer cases, no data about TSH suppression, and short follow-up periods, no significant difference in BMD with or without thyroid cancer was observed. The subgroup analyses of women and post-menopausal women showed similar results.

Copyright © 2019. Korean Association of Medical Journal Editors.